By inhibiting tumor hypoxia, anti-hypoxia therapy reduces the expression of CD39 on the most terminally exhausted T cells, limiting its regulatory potential and promoting the improvement of CD8 + T cell effector function [210]. This evidence concerns the gene CD8A and neoplasm.